-
1
-
-
0017059806
-
Short-term results of combined radioimmunotherapy in inoperable lung cancer
-
PubMed
-
Curcio, C.G.; Vasile, C.; Gianciotta, A.; Casali, A.; Gionfra, T.; Rinaldi, M.; Guadagni, A.; Le Pera, V.; Sega, E. Short-term results of combined radioimmunotherapy in inoperable lung cancer. Tumori 1976, 62, 587–598. [PubMed]
-
(1976)
Tumori
, vol.62
, pp. 587-598
-
-
Curcio, C.G.1
Vasile, C.2
Gianciotta, A.3
Casali, A.4
Gionfra, T.5
Rinaldi, M.6
Guadagni, A.7
Le Pera, V.8
Sega, E.9
-
2
-
-
0019981777
-
Radioimmunodiagnosis and radioimmunotherapy
-
PubMed
-
Sfakianakis, G.N.; DeLand, F.H. Radioimmunodiagnosis and radioimmunotherapy, 1982. J. Nucl. Med. 1982, 23, 840–850. [PubMed]
-
(1982)
J. Nucl. Med
, vol.1982
, Issue.23
, pp. 840-850
-
-
Sfakianakis, G.N.1
Deland, F.H.2
-
3
-
-
0025801780
-
Radioimmunotherapy of malignancies
-
PubMed
-
Reilly, R.M. Radioimmunotherapy of malignancies. Clin. Pharm. 1991, 10, 359–375. [PubMed]
-
(1991)
Clin. Pharm
, vol.10
, pp. 359-375
-
-
Reilly, R.M.1
-
4
-
-
84864559416
-
Pretargeted molecular imaging and radioimmunotherapy
-
[CrossRef][PubMed]
-
Goldenberg, D.M.; Chang, C.H.; Rossi, E.A.; McBride, J.W.; Sharkey, R.M. Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2012, 2, 523–540. [CrossRef][PubMed]
-
(2012)
Theranostics
, vol.2
, pp. 523-540
-
-
Goldenberg, D.M.1
Chang, C.H.2
Rossi, E.A.3
McBride, J.W.4
Sharkey, R.M.5
-
5
-
-
85061995607
-
Navarro-Teulon, I. Introduction to radiobiology of targeted radionuclide therapy
-
[CrossRef][PubMed]
-
Pouget, J.P.; Lozza, C.; Deshayes, E.; Boudousq, V.; Navarro-Teulon, I. Introduction to radiobiology of targeted radionuclide therapy. Front. Med. 2015, 2. [CrossRef][PubMed]
-
(2015)
Front. Med
-
-
Pouget, J.P.1
Lozza, C.2
Deshayes, E.3
Boudousq, V.4
-
6
-
-
84919464054
-
Radiotherapy and immunogenic cell death
-
[CrossRef][PubMed]
-
Golden, E.B.; Apetoh, L. Radiotherapy and immunogenic cell death. Semin. Radiat. Oncol. 2015, 25, 11–17. [CrossRef][PubMed]
-
(2015)
Semin. Radiat. Oncol
, vol.25
, pp. 11-17
-
-
Golden, E.B.1
Apetoh, L.2
-
7
-
-
0024195429
-
DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation, and reparability
-
[PubMed]
-
Ward, J.F. DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation, and reparability. Prog. Nucleic Acid Res. Mol. Biol. 1988, 35, 95–125. [PubMed]
-
(1988)
Prog. Nucleic Acid Res. Mol. Biol
, vol.35
, pp. 95-125
-
-
Ward, J.F.1
-
8
-
-
84883300098
-
Advances in anticancer radiopharmaceuticals
-
[CrossRef][PubMed]
-
Jackson, M.R.; Falzone, N.; Vallis, K.A. Advances in anticancer radiopharmaceuticals. Clin. Oncol. 2013, 25, 604–609. [CrossRef][PubMed]
-
(2013)
Clin. Oncol
, vol.25
, pp. 604-609
-
-
Jackson, M.R.1
Falzone, N.2
Vallis, K.A.3
-
9
-
-
14844359242
-
Radiobiologic principles in radionuclide therapy
-
PubMed
-
Kassis, A.I.; Adelstein, S.J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46, 4S–12S. [PubMed]
-
(2005)
J. Nucl. Med
, vol.46
-
-
Kassis, A.I.1
Adelstein, S.J.2
-
10
-
-
84961060184
-
Effects of different radiations on human cells in tissue culture. Ii. Biological experiments
-
[CrossRef][PubMed]
-
Barendsen, G.W.; Beusker, T.L.; Vergroesen, A.J.; Budke, L. Effects of different radiations on human cells in tissue culture. Ii. Biological experiments. Radiat. Res. 1960, 13, 841–849. [CrossRef][PubMed]
-
(1960)
Radiat. Res
, vol.13
, pp. 841-849
-
-
Barendsen, G.W.1
Beusker, T.L.2
Vergroesen, A.J.3
Budke, L.4
-
11
-
-
0034975275
-
Therapeutic radionuclides and nuclear data
-
CrossRef
-
Qaim, S.M. Therapeutic radionuclides and nuclear data. Radiochim. Acta 2001, 89, 297–302. [CrossRef]
-
(2001)
Radiochim. Acta
, vol.89
, pp. 297-302
-
-
Qaim, S.M.1
-
12
-
-
84862682101
-
Effective use of strontium-89 in osseous metastases
-
[CrossRef][PubMed]
-
Kuroda, I. Effective use of strontium-89 in osseous metastases. Ann. Nucl. Med. 2012, 26, 197–206. [CrossRef][PubMed]
-
(2012)
Ann. Nucl. Med
, vol.26
, pp. 197-206
-
-
Kuroda, I.1
-
13
-
-
0034145611
-
The aapm/rsna physics tutorial for residents: Internal radiation dosimetry: Principles and applications
-
[CrossRef][PubMed]
-
Toohey, R.E.; Stabin, M.G.; Watson, E.E. The aapm/rsna physics tutorial for residents: Internal radiation dosimetry: Principles and applications. Radiographics 2000, 20, 533–546. [CrossRef][PubMed]
-
(2000)
Radiographics
, vol.20
, pp. 533-546
-
-
Toohey, R.E.1
Stabin, M.G.2
Watson, E.E.3
-
14
-
-
84868191187
-
Fractionated radioimmunotherapy with (90) y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial
-
CrossRefPubMed
-
Ocean, A.J.; Pennington, K.L.; Guarino, M.J.; Sheikh, A.; Bekaii-Saab, T.; Serafini, A.N.; Lee, D.; Sung, M.W.; Gulec, S.A.; Goldsmith, S.J.; et al. Fractionated radioimmunotherapy with (90) y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 2012, 118, 5497–5506. [CrossRef][PubMed]
-
(2012)
Cancer
, vol.118
, pp. 5497-5506
-
-
Ocean, A.J.1
Pennington, K.L.2
Guarino, M.J.3
Sheikh, A.4
Bekaii-Saab, T.5
Serafini, A.N.6
Lee, D.7
Sung, M.W.8
Gulec, S.A.9
Goldsmith, S.J.10
-
15
-
-
84926430481
-
A pretargeting system for tumor pet imaging and radioimmunotherapy
-
CrossRef
-
Kraeber-Bodere, F.; Rousseau, C.; Bodet-Milin, C.; Frampas, E.; Faivre-Chauvet, A.; Rauscher, A.; Sharkey, R.M.; Goldenberg, D.M.; Chatal, J.F.; Barbet, J. A pretargeting system for tumor pet imaging and radioimmunotherapy. Front. Pharmacol. 2015, 6. [CrossRef]
-
(2015)
Front. Pharmacol
-
-
Kraeber-Bodere, F.1
Rousseau, C.2
Bodet-Milin, C.3
Frampas, E.4
Faivre-Chauvet, A.5
Rauscher, A.6
Sharkey, R.M.7
Goldenberg, D.M.8
Chatal, J.F.9
Barbet, J.10
-
16
-
-
79959430516
-
Astatine-211: Production and availability
-
CrossRefPubMed
-
Zalutsky, M.R.; Pruszynski, M. Astatine-211: Production and availability. Curr. Radiopharm. 2011, 4, 177–185. [CrossRef][PubMed]
-
(2011)
Curr. Radiopharm
, vol.4
, pp. 177-185
-
-
Zalutsky, M.R.1
Pruszynski, M.2
-
17
-
-
84952663063
-
-
Vienna, Austria
-
Abmel, X.C.; Chinol, M.; Jin, X.-H.; Knapp, F.F., Jr.; Rostislav, K.; van So, L.; Renata, M.; Fabiola, M.; Osso, J.A.; Park, S.H.; et al. Therapeutic Radionuclide Generators: 90sr/90y and 188w/188re Generators; International Atomic Energy Agency: Vienna, Austria, 2009; p. 235.
-
(2009)
Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators; International Atomic Energy Agency
-
-
Abmel, X.C.1
Chinol, M.2
Jin, X.-H.3
Knapp, F.F.4
Rostislav, K.5
Van So, L.6
Renata, M.7
Fabiola, M.8
Osso, J.A.9
Park, S.H.10
-
18
-
-
84863556127
-
Rhenium-188: Availability from the (188)w/(188)re generator and status of current applications
-
CrossRefPubMed
-
Pillai, M.R.; Dash, A.; Knapp, F.F., Rhenium-188: Availability from the (188)w/(188)re generator and status of current applications. Curr. Radiopharm. 2012, 5, 228–243. [CrossRef][PubMed]
-
(2012)
Curr. Radiopharm
, vol.5
, pp. 228-243
-
-
Pillai, M.R.1
Dash, A.2
Knapp, F.F.3
-
19
-
-
84929910660
-
Radioimmunotherapy of human tumours
-
CrossRefPubMed
-
Larson, S.M.; Carrasquillo, J.A.; Cheung, N.K.; Press, O.W. Radioimmunotherapy of human tumours. Nat. Rev. Cancer 2015, 15, 347–360. [CrossRef][PubMed]
-
(2015)
Nat. Rev. Cancer
, vol.15
, pp. 347-360
-
-
Larson, S.M.1
Carrasquillo, J.A.2
Cheung, N.K.3
Press, O.W.4
-
20
-
-
9244224115
-
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
-
PubMed
-
Press, O.W.; Shan, D.; Howell-Clark, J.; Eary, J.; Appelbaum, F.R.; Matthews, D.; King, D.J.; Haines, A.M.; Hamann, P.; Hinman, L.; et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996, 56, 2123–2129. [PubMed]
-
(1996)
Cancer Res
, vol.56
, pp. 2123-2129
-
-
Press, O.W.1
Shan, D.2
Howell-Clark, J.3
Eary, J.4
Appelbaum, F.R.5
Matthews, D.6
King, D.J.7
Haines, A.M.8
Hamann, P.9
Hinman, L.10
-
21
-
-
78349269462
-
New antibody conjugates in cancer therapy
-
CrossRefPubMed
-
Govindan, S.V.; Goldenberg, D.M. New antibody conjugates in cancer therapy. Sci. World J. 2010, 10, 2070–2089. [CrossRef][PubMed]
-
(2010)
Sci. World J
, vol.10
, pp. 2070-2089
-
-
Govindan, S.V.1
Goldenberg, D.M.2
-
22
-
-
84900389533
-
Radioimmunotherapy with alpha-particle-emitting radionuclides
-
CrossRefPubMed
-
Seidl, C. Radioimmunotherapy with alpha-particle-emitting radionuclides. Immunotherapy 2014, 6, 431–458. [CrossRef][PubMed]
-
(2014)
Immunotherapy
, vol.6
, pp. 431-458
-
-
Seidl, C.1
-
23
-
-
84908322778
-
Radiolabeled apoptosis imaging agents for early detection of response to therapy
-
CrossRef][PubMed
-
Ogawa, K.; Aoki, M. Radiolabeled apoptosis imaging agents for early detection of response to therapy. Sci. World J. 2014, 2014, 732603. [CrossRef][PubMed]
-
Sci. World J
, vol.2014
, pp. 2014
-
-
Ogawa, K.1
Aoki, M.2
-
24
-
-
84929408050
-
Radioiodine therapy in differentiated thyroid cancer: The first targeted therapy in oncology
-
CrossRefPubMed
-
Chung, J.K.; Cheon, G.J. Radioiodine therapy in differentiated thyroid cancer: The first targeted therapy in oncology. Endocrinol. Metab. 2014, 29, 233–239. [CrossRef][PubMed]
-
(2014)
Endocrinol. Metab.
, vol.29
, pp. 233-239
-
-
Chung, J.K.1
Cheon, G.J.2
-
25
-
-
0025667672
-
Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid
-
CrossRef
-
Seidlin, S.M.; Marinelli, L.D.; Oshry, E. Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid. J. Am. Med. Assoc. 1990, 40, 299–317. [CrossRef]
-
(1990)
J. Am. Med. Assoc
, vol.40
, pp. 299-317
-
-
Seidlin, S.M.1
Marinelli, L.D.2
Oshry, E.3
-
26
-
-
0030053759
-
Cloning and characterization of the thyroid iodide transporter
-
[CrossRef][PubMed]
-
Dai, G.; Levy, O.; Carrasco, N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379, 458–460. [CrossRef][PubMed]
-
(1996)
Nature
, vol.379
, pp. 458-460
-
-
Dai, G.1
Levy, O.2
Carrasco, N.3
-
27
-
-
79955046955
-
Feasibility of a novel positive feedback effect of 131i-promoted bac-egr1-hnis expression in malignant glioma through baculovirus
-
[CrossRef][PubMed]
-
Guo, R.; Zhang, R.; Pan, Y.; Xu, H.; Zhang, M.; Liang, S.; Wang, L.; Zhang, Y.; Li, B. Feasibility of a novel positive feedback effect of 131i-promoted bac-egr1-hnis expression in malignant glioma through baculovirus: A comparative study with bac-cmv-hnis. Nucl. Med. Commun. 2011, 32, 402–409. [CrossRef][PubMed]
-
(2011)
A Comparative Study with Bac-Cmv-Hnis. Nucl. Med. Commun.
, vol.32
, pp. 402-409
-
-
Guo, R.1
Zhang, R.2
Pan, Y.3
Xu, H.4
Zhang, M.5
Liang, S.6
Wang, L.7
Zhang, Y.8
Li, B.9
-
28
-
-
35348857500
-
The importance of sodium/iodide symporter (Nis) for thyroid cancer management
-
CrossRef
-
Carvalho, D.P.; Ferreira, A.C. The importance of sodium/iodide symporter (nis) for thyroid cancer management. Arq. Bras. Endocrinol. Metab. 2007, 51, 672–682. [CrossRef]
-
(2007)
Arq. Bras. Endocrinol. Metab
, vol.51
, pp. 672-682
-
-
Carvalho, D.P.1
Ferreira, A.C.2
-
29
-
-
1442348110
-
Transcriptional regulation of human sodium/iodide symporter gene: A role for redox factor-1
-
[CrossRef][PubMed]
-
Puppin, C.; Arturi, F.; Ferretti, E.; Russo, D.; Sacco, R.; Tell, G.; Damante, G.; Filetti, S. Transcriptional regulation of human sodium/iodide symporter gene: A role for redox factor-1. Endocrinology 2004, 145, 1290–1293. [CrossRef][PubMed]
-
(2004)
Endocrinology
, vol.145
, pp. 1290-1293
-
-
Puppin, C.1
Arturi, F.2
Ferretti, E.3
Russo, D.4
Sacco, R.5
Tell, G.6
Damante, G.7
Filetti, S.8
-
30
-
-
77956115891
-
Nf-kappab p65 subunit mediates lipopolysaccharide-induced Na(+)/I(-) symporter gene expression by involving functional interaction with the paired domain transcription factor pax8
-
[CrossRef][PubMed]
-
Nicola, J.P.; Nazar, M.; Mascanfroni, I.D.; Pellizas, C.G.; Masini-Repiso, A.M. Nf-kappab p65 subunit mediates lipopolysaccharide-induced Na(+)/I(-) symporter gene expression by involving functional interaction with the paired domain transcription factor pax8. Mol. Endocrinol. 2010, 24, 1846–1862. [CrossRef][PubMed]
-
(2010)
Mol. Endocrinol
, vol.24
, pp. 1846-1862
-
-
Nicola, J.P.1
Nazar, M.2
Mascanfroni, I.D.3
Pellizas, C.G.4
Masini-Repiso, A.M.5
-
31
-
-
79952736015
-
Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma
-
[CrossRef][PubMed]
-
Chung, J.-K.; Youn, H.W.; Kang, J.H.; Lee, H.Y.; Kang, K.W. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl. Med. Mol. Imaging 2010, 44, 4–14. [CrossRef][PubMed]
-
(2010)
Nucl. Med. Mol. Imaging
, vol.44
, pp. 4-14
-
-
Chung, J.-K.1
Youn, H.W.2
Kang, J.H.3
Lee, H.Y.4
Kang, K.W.5
-
32
-
-
84897939554
-
Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: Alpha therapy with 223ra-dichloride
-
[CrossRef][PubMed]
-
Pandit-Taskar, N.; Larson, S.M.; Carrasquillo, J.A. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: Alpha therapy with 223ra-dichloride. J. Nucl. Med. 2014, 55, 268–274. [CrossRef][PubMed]
-
(2014)
J. Nucl. Med
, vol.55
, pp. 268-274
-
-
Pandit-Taskar, N.1
Larson, S.M.2
Carrasquillo, J.A.3
-
33
-
-
84859476468
-
The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases
-
PubMed
-
Tomblyn, M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control 2012, 19, 137–144. [PubMed]
-
(2012)
Cancer Control
, vol.19
, pp. 137-144
-
-
Tomblyn, M.1
-
34
-
-
84945119633
-
New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Q
-
PubMed
-
Maffioli, L.; Florimonte, L.; Costa, D.C.; Correia Castanheira, J.; Grana, C.; Luster, M.; Bodei, L.; Chinol, M. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Q. J. Nucl. Med. Mol. Imaging 2015, 59, 420–438. [PubMed]
-
(2015)
J. Nucl. Med. Mol. Imaging
, vol.59
, pp. 420-438
-
-
Maffioli, L.1
Florimonte, L.2
Costa, D.C.3
Correia Castanheira, J.4
Grana, C.5
Luster, M.6
Bodei, L.7
Chinol, M.8
-
35
-
-
84952671433
-
Systemic targeted alpha radiotherapy for cancer
-
[CrossRef][PubMed]
-
Allen, B. Systemic targeted alpha radiotherapy for cancer. J. Biomed. Phys. Eng. 2013, 3, 67–80. [CrossRef][PubMed]
-
(2013)
J. Biomed. Phys. Eng
, vol.3
, pp. 67-80
-
-
Allen, B.1
-
36
-
-
84891472678
-
Targeted radionuclide therapy—An overview
-
[CrossRef][PubMed]
-
Dash, A.; Knapp, F.F.; Pillai, M.R. Targeted radionuclide therapy—An overview. Curr. Radiopharm. 2013, 6, 152–180. [CrossRef][PubMed]
-
(2013)
Curr. Radiopharm
, vol.6
, pp. 152-180
-
-
Dash, A.1
Knapp, F.F.2
Pillai, M.R.3
-
37
-
-
84858785688
-
Antibody therapy of cancer
-
[CrossRef][PubMed]
-
Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12, 278–287. [CrossRef][PubMed]
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 278-287
-
-
Scott, A.M.1
Wolchok, J.D.2
Old, L.J.3
-
38
-
-
84929885314
-
Building better monoclonal antibody-based therapeutics
-
[CrossRef][PubMed]
-
Weiner, G.J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 2015, 15, 361–370. [CrossRef][PubMed]
-
(2015)
. Rev. Cancer
, vol.15
, pp. 361-370
-
-
Weiner, G.1
-
39
-
-
84907044887
-
Peptide receptor radionuclide therapy for advanced neuroendocrine tumors
-
[CrossRef][PubMed]
-
Bodei, L.; Cremonesi, M.; Kidd, M.; Grana, C.M.; Severi, S.; Modlin, I.M.; Paganelli, G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac. Surg. Clin. 2014, 24, 333–349. [CrossRef][PubMed]
-
(2014)
Thorac. Surg. Clin
, vol.24
, pp. 333-349
-
-
Bodei, L.1
Cremonesi, M.2
Kidd, M.3
Grana, C.M.4
Severi, S.5
Modlin, I.M.6
Paganelli, G.7
-
40
-
-
84901944842
-
Peptides for diagnosis and treatment of colorectal cancer
-
[CrossRef][PubMed]
-
Shapira, S.; Fokra, A.; Arber, N.; Kraus, S. Peptides for diagnosis and treatment of colorectal cancer. Curr. Med. Chem. 2014, 21, 2410–2416. [CrossRef][PubMed]
-
(2014)
Curr. Med. Chem.
, vol.21
, pp. 2410-2416
-
-
Shapira, S.1
Fokra, A.2
Arber, N.3
Kraus, S.4
-
41
-
-
84928898755
-
Multifunctional nanoparticles for use in theranostic applications
-
[CrossRef][PubMed]
-
Cole, J.T.; Holland, N.B. Multifunctional nanoparticles for use in theranostic applications. Drug Deliv. Transl. Res. 2015, 5, 295–309. [CrossRef][PubMed]
-
(2015)
Drug Deliv. Transl. Res
, vol.5
, pp. 295-309
-
-
Cole, J.T.1
Holland, N.B.2
-
42
-
-
84940956193
-
Toward a full understanding of the epr effect in primary and metastatic tumors as well as issues related to its heterogeneity
-
[CrossRef][PubMed]
-
Maeda, H. Toward a full understanding of the epr effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 2015, 91, 3–6. [CrossRef][PubMed]
-
(2015)
Adv. Drug Deliv. Rev
, vol.91
, pp. 3-6
-
-
Maeda, H.1
-
43
-
-
84907164048
-
Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-edtmp and radium-223
-
PubMed
-
Anderson, P.M.; Subbiah, V.; Rohren, E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-edtmp and radium-223. Adv. Exp. Med. Biol. 2014, 804, 291–304. [PubMed]
-
(2014)
Adv. Exp. Med. Biol.
, vol.804
, pp. 291-304
-
-
Anderson, P.M.1
Subbiah, V.2
Rohren, E.3
-
44
-
-
35748943826
-
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol
-
[CrossRef][PubMed]
-
Hofmeister, V.; Schrama, D.; Becker, J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 2008, 57, 1–17. [CrossRef][PubMed]
-
(2008)
Immunother
, vol.57
, pp. 1-17
-
-
Hofmeister, V.1
Schrama, D.2
Becker, J.C.3
-
45
-
-
84933505636
-
Monoclonal antibodies in acute lymphoblastic leukemia
-
[CrossRef][PubMed]
-
Jabbour, E.; O’Brien, S.; Ravandi, F.; Kantarjian, H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood 2015, 125, 4010–4016. [CrossRef][PubMed]
-
(2015)
Blood
, vol.125
, pp. 4010-4016
-
-
Jabbour, E.1
O’Brien, S.2
Ravandi, F.3
Kantarjian, H.4
-
46
-
-
84904251878
-
Practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia
-
[CrossRef][PubMed]
-
Seifert, R.P.; Bulkeley, W.,; Zhang, L.; Menes, M.; Bui, M.M. A practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia. Ann. Diagn. Pathol. 2014, 18, 253–260. [CrossRef][PubMed]
-
(2014)
Ann. Diagn. Pathol
, vol.18
, pp. 253-260
-
-
Seifert, R.P.1
Bulkeley, W.2
Zhang, L.3
Menes, M.4
Bui, M.5
-
47
-
-
84952656924
-
Biomarkers for immunotherapy in genitourinary malignancies
-
[CrossRef][PubMed]
-
Slovin, S. Biomarkers for immunotherapy in genitourinary malignancies. Urol. Oncol. 2015, 18, 253–260. [CrossRef][PubMed]
-
(2015)
Urol. Oncol
, vol.18
, pp. 253-260
-
-
Slovin, S.1
-
48
-
-
68349091432
-
Delivering cytokines at tumor site: The immunocytokine-conjugated anti-edb-fibronectin antibody case
-
[CrossRef][PubMed]
-
Ronca, R.; Sozzani, S.; Presta, M.; Alessi, P. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-edb-fibronectin antibody case. Immunobiology 2009, 214, 800–810. [CrossRef][PubMed]
-
(2009)
Immunobiology
, vol.214
, pp. 800-810
-
-
Ronca, R.1
Sozzani, S.2
Presta, M.3
Alessi, P.4
-
49
-
-
0029832918
-
Organ-specific expression of the colon cancer antigen a33, a cell surface target for antibody-based therapy
-
[CrossRef][PubMed]
-
Garinchesa, P.; Sakamoto, J.; Welt, S.; Real, F.; Rettig, W.; Old, L. Organ-specific expression of the colon cancer antigen a33, a cell surface target for antibody-based therapy. Int. J. Oncol. 1996, 9, 465–471. [CrossRef][PubMed]
-
(1996)
Int. J. Oncol
, vol.9
, pp. 465-471
-
-
Garinchesa, P.1
Sakamoto, J.2
Welt, S.3
Real, F.4
Rettig, W.5
Old, L.6
-
50
-
-
84865410155
-
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treat
-
[CrossRef][PubMed]
-
Huang, C.Y.; Pourgholami, M.H.; Allen, B.J. Optimizing radioimmunoconjugate delivery in the treatment of solid tumor. Cancer Treat. Rev. 2012, 38, 854–860. [CrossRef][PubMed]
-
(2012)
Rev
, vol.38
, pp. 854-860
-
-
Huang, C.Y.1
Pourgholami, M.H.2
Allen, B.J.3
-
51
-
-
84875965291
-
Radioimmunotherapy for hematopoietic cell transplantation
-
[CrossRef][PubMed]
-
Jurcic, J.G. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy 2013, 5, 383–394. [CrossRef][PubMed]
-
(2013)
Immunotherapy
, vol.5
, pp. 383-394
-
-
Jurcic, J.G.1
-
52
-
-
84936153380
-
Cd5- and cd23-positive splenic diffuse large b-cell lymphoma with very low cd20 expression
-
[CrossRef][PubMed]
-
Tabata, R.; Iwama, H.; Tabata, C.; Yasumizu, R.; Kojima, M. Cd5- and cd23-positive splenic diffuse large b-cell lymphoma with very low cd20 expression. J. Clin. Exp. Hematop. 2014, 54, 155–161. [CrossRef][PubMed]
-
(2014)
J. Clin. Exp. Hematop
, vol.54
, pp. 155-161
-
-
Tabata, R.1
Iwama, H.2
Tabata, C.3
Yasumizu, R.4
Kojima, M.5
-
53
-
-
0034501637
-
Anti-cd30 antibody-based therapy
-
[CrossRef][PubMed]
-
Koon, H.B.; Junghans, R.P. Anti-cd30 antibody-based therapy. Curr. Opin. Oncol. 2000, 12, 588–593. [CrossRef][PubMed]
-
(2000)
Curr. Opin. Oncol
, vol.12
, pp. 588-593
-
-
Koon, H.B.1
Junghans, R.P.2
-
54
-
-
33748045787
-
The anti-cd25 monoclonal antibody 7g7/b6, armed with the alpha-emitter 211at, provides effective radioimmunotherapy for a murine model of leukemia
-
[CrossRef][PubMed]
-
Zhang, M.; Yao, Z.; Zhang, Z.; Garmestani, K.; Talanov, V.S.; Plascjak, P.S.; Yu, S.; Kim, H.S.; Goldman, C.K.; Paik, C.H.; et al. The anti-cd25 monoclonal antibody 7g7/b6, armed with the alpha-emitter 211at, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res. 2006, 66, 8227–8232. [CrossRef][PubMed]
-
(2006)
Cancer Res
, vol.66
, pp. 8227-8232
-
-
Zhang, M.1
Yao, Z.2
Zhang, Z.3
Garmestani, K.4
Talanov, V.S.5
Plascjak, P.S.6
Yu, S.7
Kim, H.S.8
Goldman, C.K.9
Paik, C.H.10
-
55
-
-
27244458791
-
Phase ii trial of carcinoembryonic antigen radioimmunotherapy with 131i-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results
-
[CrossRef][PubMed]
-
Liersch, T.; Meller, J.; Kulle, B.; Behr, T.M.; Markus, P.; Langer, C.; Ghadimi, B.M.; Wegener, W.A.; Kovacs, J.; Horak, I.D.; et al. Phase ii trial of carcinoembryonic antigen radioimmunotherapy with 131i-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J. Clin. Oncol. 2005, 23, 6763–6770. [CrossRef][PubMed]
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 6763-6770
-
-
Liersch, T.1
Meller, J.2
Kulle, B.3
Behr, T.M.4
Markus, P.5
Langer, C.6
Ghadimi, B.M.7
Wegener, W.A.8
Kovacs, J.9
Horak, I.D.10
-
56
-
-
84884536175
-
Phase ii study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody j591 for metastatic castration-resistant prostate cancer
-
[CrossRef][PubMed]
-
Tagawa, S.T.; Milowsky, M.I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N.H.; Osborne, J.; Goldsmith, S.J.; Larson, S.; Taskar, N.P.; et al. Phase ii study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody j591 for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2013, 19, 5182–5191. [CrossRef][PubMed]
-
(2013)
Clin. Cancer Res
, vol.19
, pp. 5182-5191
-
-
Tagawa, S.T.1
Milowsky, M.I.2
Morris, M.3
Vallabhajosula, S.4
Christos, P.5
Akhtar, N.H.6
Osborne, J.7
Goldsmith, S.J.8
Larson, S.9
Taskar, N.P.10
-
57
-
-
38049170147
-
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
-
[CrossRef][PubMed]
-
Raja, C.; Graham, P.; Abbas Rizvi, S.M.; Song, E.; Goldsmith, H.; Thompson, J.; Bosserhoff, A.; Morgenstern, A.; Apostolidis, C.; Kearsley, J.; et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 2007, 6, 846–852. [CrossRef][PubMed]
-
(2007)
Cancer Biol. Ther
, vol.6
, pp. 846-852
-
-
Raja, C.1
Graham, P.2
Abbas Rizvi, S.M.3
Song, E.4
Goldsmith, H.5
Thompson, J.6
Bosserhoff, A.7
Morgenstern, A.8
Apostolidis, C.9
Kearsley, J.10
-
58
-
-
80053000534
-
Analysis of patient survival in a phase I trial of systemic targeted alpha-therapy for metastatic melanoma
-
[CrossRef][PubMed]
-
Allen, B.J.; Singla, A.A.; Rizvi, S.M.; Graham, P.; Bruchertseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of patient survival in a phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 2011, 3, 1041–1050. [CrossRef][PubMed]
-
(2011)
Immunotherapy
, vol.3
, pp. 1041-1050
-
-
Allen, B.J.1
Singla, A.A.2
Rizvi, S.M.3
Graham, P.4
Bruchertseifer, F.5
Apostolidis, C.6
Morgenstern, A.7
-
59
-
-
84879188286
-
Treatment with the radiolabelled somatostatin analog lu-dotatate for advanced pancreatic neuroendocrine tumors
-
[CrossRef][PubMed]
-
Sansovini, M.; Severi, S.; Ambrosetti, A.; Monti, M.; Nanni, O.; Sarnelli, A.; Bodei, L.; Garaboldi, L.; Bartolomei, M.; Paganelli, G. Treatment with the radiolabelled somatostatin analog lu-dotatate for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 2013, 97, 347–354. [CrossRef][PubMed]
-
(2013)
Neuroendocrinology
, vol.97
, pp. 347-354
-
-
Sansovini, M.1
Severi, S.2
Ambrosetti, A.3
Monti, M.4
Nanni, O.5
Sarnelli, A.6
Bodei, L.7
Garaboldi, L.8
Bartolomei, M.9
Paganelli, G.10
-
60
-
-
32144463528
-
Targeted radionuclide therapy with 90y-dotatoc in patients with neuroendocrine tumors
-
PubMed
-
Forrer, F.; Waldherr, C.; Maecke, H.R.; Mueller-Brand, J. Targeted radionuclide therapy with 90y-dotatoc in patients with neuroendocrine tumors. Anticancer Res. 2006, 26, 703–707. [PubMed]
-
(2006)
Anticancer Res
, vol.26
, pp. 703-707
-
-
Forrer, F.1
Waldherr, C.2
Maecke, H.R.3
Mueller-Brand, J.4
-
61
-
-
0036250672
-
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 gbq (90)y-dotatoc. J
-
PubMed
-
Waldherr, C.; Pless, M.; Maecke, H.R.; Schumacher, T.; Crazzolara, A.; Nitzsche, E.U.; Haldemann, A.; Mueller-Brand, J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 gbq (90)y-dotatoc. J. Nucl. Med. 2002, 43, 610–616. [PubMed]
-
(2002)
Nucl. Med
, vol.43
, pp. 610-616
-
-
Waldherr, C.1
Pless, M.2
Maecke, H.R.3
Schumacher, T.4
Crazzolara, A.5
Nitzsche, E.U.6
Haldemann, A.7
Mueller-Brand, J.8
-
62
-
-
79954439894
-
Yttrium-90 dotatoc therapy in gep-net and other sst2 expressing tumors: A selected review
-
[CrossRef][PubMed]
-
Nisa, L.; Savelli, G.; Giubbini, R. Yttrium-90 dotatoc therapy in gep-net and other sst2 expressing tumors: A selected review. Ann. Nucl. Med. 2011, 25, 75–85. [CrossRef][PubMed]
-
(2011)
Ann. Nucl. Med
, vol.25
, pp. 75-85
-
-
Nisa, L.1
Savelli, G.2
Giubbini, R.3
-
63
-
-
84939464135
-
Targeted radionuclide therapies for pancreatic cancer
-
[CrossRef][PubMed]
-
Shah, M.; da Silva, R.; Gravekamp, C.; Libutti, S.K.; Abraham, T.; Dadachova, E. Targeted radionuclide therapies for pancreatic cancer. Cancer Gene Ther. 2015, 22, 375–379. [CrossRef][PubMed]
-
(2015)
Cancer Gene Ther
, vol.22
, pp. 375-379
-
-
Shah, M.1
Da Silva, R.2
Gravekamp, C.3
Libutti, S.K.4
Abraham, T.5
Dadachova, E.6
-
64
-
-
84909645101
-
Radioimmunoconjugates for the treatment of cancer. Semin
-
[CrossRef][PubMed]
-
Kraeber-Bodere, F.; Bodet-Milin, C.; Rousseau, C.; Eugene, T.; Pallardy, A.; Frampas, E.; Carlier, T.; Ferrer, L.; Gaschet, J.; Davodeau, F.; et al. Radioimmunoconjugates for the treatment of cancer. Semin. Oncol. 2014, 41, 613–622. [CrossRef][PubMed]
-
(2014)
Oncol
, vol.41
, pp. 613-622
-
-
Kraeber-Bodere, F.1
Bodet-Milin, C.2
Rousseau, C.3
Eugene, T.4
Pallardy, A.5
Frampas, E.6
Carlier, T.7
Ferrer, L.8
Gaschet, J.9
Davodeau, F.10
-
66
-
-
0029928295
-
Normal tissue radiosensitivity–how important is it? Clin
-
CrossRef
-
Burnet, N.G.; Wurm, R.; Nyman, J.; Peacock, J.H. Normal tissue radiosensitivity–how important is it? Clin. Oncol. 1996, 8, 25–34. [CrossRef]
-
(1996)
Oncol
, vol.8
, pp. 25-34
-
-
Burnet, N.G.1
Wurm, R.2
Nyman, J.3
Peacock, J.H.4
-
67
-
-
33746707858
-
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223ra: Adjuvant or alternative to conventional modalities? Clin
-
[CrossRef][PubMed]
-
Bruland, O.S.; Nilsson, S.; Fisher, D.R.; Larsen, R.H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223ra: Adjuvant or alternative to conventional modalities? Clin. Cancer Res. 2006, 12, 6250s–6257s. [CrossRef][PubMed]
-
(2006)
Cancer Res
, vol.12
, pp. 6250s-6257s
-
-
Bruland, O.S.1
Nilsson, S.2
Fisher, D.R.3
Larsen, R.H.4
-
68
-
-
84956571721
-
Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with i-metaiodobenzylguanidine (Mibg)
-
CrossRef
-
Trieu, M.; DuBois, S.G.; Pon, E.; Nardo, L.; Hawkins, R.A.; Marachelian, A.; Twist, C.J.; Park, J.R.; Matthay, K.K. Impact of whole-body radiation dose on response and toxicity in patients with neuroblastoma after therapy with i-metaiodobenzylguanidine (mibg). Pediatr. Blood Cancer 2016, 63. [CrossRef]
-
(2016)
Pediatr. Blood Cancer
-
-
Trieu, M.1
Dubois, S.G.2
Pon, E.3
Nardo, L.4
Hawkins, R.A.5
Marachelian, A.6
Twist, C.J.7
Park, J.R.8
Matthay, K.K.9
-
69
-
-
84870403525
-
Tumor dosimetry using [124i]m-iodobenzylguanidine micropet/ct for [131i]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model
-
[CrossRef][PubMed]
-
Seo, Y.; Gustafson, W.C.; Dannoon, S.F.; Nekritz, E.A.; Lee, C.L.; Murphy, S.T.; VanBrocklin, H.F.; Hernandez-Pampaloni, M.; Haas-Kogan, D.A.; Weiss, W.A.; et al. Tumor dosimetry using [124i]m-iodobenzylguanidine micropet/ct for [131i]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol. Imaging Biol. 2012, 14, 735–742. [CrossRef][PubMed]
-
(2012)
Mol. Imaging Biol
, vol.14
, pp. 735-742
-
-
Seo, Y.1
Gustafson, W.C.2
Dannoon, S.F.3
Nekritz, E.A.4
Lee, C.L.5
Murphy, S.T.6
Vanbrocklin, H.F.7
Hernandez-Pampaloni, M.8
Haas-Kogan, D.A.9
Weiss, W.A.10
-
70
-
-
84924601329
-
Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mibg) dynamic pet/ct imaging before [131I]mibg targeted radionuclide therapy for neuroblastoma. Mol
-
[CrossRef][PubMed]
-
Huang, S.Y.; Bolch, W.E.; Lee, C.; van Brocklin, H.F.; Pampaloni, M.H.; Hawkins, R.A.; Sznewajs, A.; DuBois, S.G.; Matthay, K.K.; Seo, Y. Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mibg) dynamic pet/ct imaging before [131I]mibg targeted radionuclide therapy for neuroblastoma. Mol. Imaging Biol. 2015, 17, 284–294. [CrossRef][PubMed]
-
(2015)
Imaging Biol
, vol.17
, pp. 284-294
-
-
Huang, S.Y.1
Bolch, W.E.2
Lee, C.3
Van Brocklin, H.F.4
Pampaloni, M.H.5
Hawkins, R.A.6
Sznewajs, A.7
Dubois, S.G.8
Matthay, K.K.9
Seo, Y.10
-
71
-
-
0031814534
-
Yttrium-90 biodistribution by yttrium-87 imaging: A theoretical feasibility analysis
-
[CrossRef][PubMed]
-
Sgouros, G. Yttrium-90 biodistribution by yttrium-87 imaging: A theoretical feasibility analysis. Med. Phys. 1998, 25, 1487–1490. [CrossRef][PubMed]
-
(1998)
Med. Phys.
, vol.25
, pp. 1487-1490
-
-
Sgouros, G.1
-
72
-
-
79959273645
-
Treatment of advanced pancreatic carcinoma with 90y-clivatuzumab tetraxetan: A phase I single-dose escalation trial
-
[CrossRef][PubMed]
-
Gulec, S.A.; Cohen, S.J.; Pennington, K.L.; Zuckier, L.S.; Hauke, R.J.; Horne, H.; Wegener, W.A.; Teoh, N.; Gold, D.V.; Sharkey, R.M.; et al. Treatment of advanced pancreatic carcinoma with 90y-clivatuzumab tetraxetan: A phase I single-dose escalation trial. Clin. Cancer Res. 2011, 17, 4091–4100. [CrossRef][PubMed]
-
(2011)
Clin. Cancer Res
, vol.17
, pp. 4091-4100
-
-
Gulec, S.A.1
Cohen, S.J.2
Pennington, K.L.3
Zuckier, L.S.4
Hauke, R.J.5
Horne, H.6
Wegener, W.A.7
Teoh, N.8
Gold, D.V.9
Sharkey, R.M.10
-
73
-
-
84919774236
-
Therapeutic radionuclides in nuclear medicine: Current and future prospects
-
[CrossRef][PubMed]
-
Yeong, C.H.; Cheng, M.H.; Ng, K.H. Therapeutic radionuclides in nuclear medicine: Current and future prospects. J. Zhejiang Univ. Sci. B 2014, 15, 845–863. [CrossRef][PubMed]
-
(2014)
J. Zhejiang Univ. Sci. B
, vol.15
, pp. 845-863
-
-
Yeong, C.H.1
Cheng, M.H.2
Ng, K.H.3
-
74
-
-
84993740454
-
Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma
-
[CrossRef][PubMed]
-
Sanchez Ruiz, A.C.; de la Cruz-Merino, L.; Provencio Pulla, M. Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. Ther. Adv. Hematol. 2014, 5, 78–90. [CrossRef][PubMed]
-
(2014)
Ther. Adv. Hematol
, vol.5
, pp. 78-90
-
-
Sanchez Ruiz, A.C.1
De La Cruz-Merino, L.2
Provencio Pulla, M.3
-
75
-
-
84880657268
-
90yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-hodgkin lymphoma: Updated results after a median follow-up of 7. 3 years from the international, randomized, phase iii first-lineindolent trial
-
[CrossRef][PubMed]
-
Morschhauser, F.; Radford, J.; van Hoof, A.; Botto, B.; Rohatiner, A.Z.; Salles, G.; Soubeyran, P.; Tilly, H.; Bischof-Delaloye, A.; van Putten, W.L.; et al. 90yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-hodgkin lymphoma: Updated results after a median follow-up of 7. 3 years from the international, randomized, phase iii first-lineindolent trial. J. Clin. Oncol. 2013, 31, 1977–1983. [CrossRef][PubMed]
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 1977-1983
-
-
Morschhauser, F.1
Radford, J.2
Van Hoof, A.3
Botto, B.4
Rohatiner, A.Z.5
Salles, G.6
Soubeyran, P.7
Tilly, H.8
Bischof-Delaloye, A.9
Van Putten, W.L.10
-
76
-
-
55949118446
-
Phase iii trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
-
[CrossRef][PubMed]
-
Morschhauser, F.; Radford, J.; van Hoof, A.; Vitolo, U.; Soubeyran, P.; Tilly, H.; Huijgens, P.C.; Kolstad, A.; d’Amore, F.; Gonzalez Diaz, M.; et al. Phase iii trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 2008, 26, 5156–5164. [CrossRef][PubMed]
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5156-5164
-
-
Morschhauser, F.1
Radford, J.2
Van Hoof, A.3
Vitolo, U.4
Soubeyran, P.5
Tilly, H.6
Huijgens, P.C.7
Kolstad, A.8
D’Amore, F.9
Gonzalez Diaz, M.10
-
77
-
-
4143123338
-
Epratuzumab, a humanized anti-cd22 antibody, in aggressive non-hodgkin's lymphoma: Phase i/ii clinical trial results
-
[CrossRef][PubMed]
-
Leonard, J.P.; Coleman, M.; Ketas, J.C.; Chadburn, A.; Furman, R.; Schuster, M.W.; Feldman, E.J.; Ashe, M.; Schuster, S.J.; Wegener, W.A.; et al. Epratuzumab, a humanized anti-cd22 antibody, in aggressive non-hodgkin's lymphoma: Phase i/ii clinical trial results. Clin. Cancer Res. 2004, 10, 5327–5334. [CrossRef][PubMed]
-
(2004)
Clin. Cancer Res
, vol.10
, pp. 5327-5334
-
-
Leonard, J.P.1
Coleman, M.2
Ketas, J.C.3
Chadburn, A.4
Furman, R.5
Schuster, M.W.6
Feldman, E.J.7
Ashe, M.8
Schuster, S.J.9
Wegener, W.A.10
-
78
-
-
77953405682
-
Muc1 immunotherapy
-
[CrossRef][PubMed]
-
Beatson, R.E.; Taylor-Papadimitriou, J.; Burchell, J.M. Muc1 immunotherapy. Immunotherapy 2010, 2, 305–327. [CrossRef][PubMed]
-
(2010)
Immunotherapy
, vol.2
, pp. 305-327
-
-
Beatson, R.E.1
Taylor-Papadimitriou, J.2
Burchell, J.M.3
-
79
-
-
84900322038
-
The role of pam4 in the management of pancreatic cancer: Diagnosis, radioimmunodetection, and radioimmunotherapy
-
[CrossRef][PubMed]
-
Han, S.; Jin, G.; Wang, L.; Li, M.; He, C.; Guo, X.; Zhu, Q. The role of pam4 in the management of pancreatic cancer: Diagnosis, radioimmunodetection, and radioimmunotherapy. J. Immunol. Res. 2014, 2014, 268479. [CrossRef][PubMed]
-
(2014)
J. Immunol. Res
, vol.2014
-
-
Han, S.1
Jin, G.2
Wang, L.3
Li, M.4
He, C.5
Guo, X.6
Zhu, Q.7
-
80
-
-
74849131675
-
Adioimmunotherapy of lymphoma: Bexxar and zevalin
-
R, [CrossRef][PubMed]
-
Goldsmith, S.J. Radioimmunotherapy of lymphoma: Bexxar and zevalin. Semin. Nucl. Med. 2010, 40, 122–135. [CrossRef][PubMed]
-
(2010)
Semin. Nucl. Med
, vol.40
, pp. 122-135
-
-
Goldsmith, S.J.1
-
81
-
-
84873397196
-
Phase iii randomized intergroup trial of chop plus rituximab compared with chop chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: Swog s0016
-
[CrossRef][PubMed]
-
Press, O.W.; Unger, J.M.; Rimsza, L.M.; Friedberg, J.W.; LeBlanc, M.; Czuczman, M.S.; Kaminski, M.; Braziel, R.M.; Spier, C.; Gopal, A.K.; et al. Phase iii randomized intergroup trial of chop plus rituximab compared with chop chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: Swog s0016. J. Clin. Oncol. 2013, 31, 314–320. [CrossRef][PubMed]
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 314-320
-
-
Press, O.W.1
Unger, J.M.2
Rimsza, L.M.3
Friedberg, J.W.4
Leblanc, M.5
Czuczman, M.S.6
Kaminski, M.7
Braziel, R.M.8
Spier, C.9
Gopal, A.K.10
-
82
-
-
84884202033
-
Phase iii randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (Beam) compared with iodine-131 tositumomab/beam with autologous hematopoietic cell transplantation for relapsed diffuse large b-cell lymphoma: Results from the bmt ctn 0401 trial
-
PubMed
-
Vose, J.M.; Carter, S.; Burns, L.J.; Ayala, E.; Press, O.W.; Moskowitz, C.H.; Stadtmauer, E.A.; Mineshi, S.; Ambinder, R.; Fenske, T.; et al. Phase iii randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (beam) compared with iodine-131 tositumomab/beam with autologous hematopoietic cell transplantation for relapsed diffuse large b-cell lymphoma: Results from the bmt ctn 0401 trial. J. Clin. Oncol. 2013, 31, 1662–1668. [PubMed]
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 1662-1668
-
-
Vose, J.M.1
Carter, S.2
Burns, L.J.3
Ayala, E.4
Press, O.W.5
Moskowitz, C.H.6
Stadtmauer, E.A.7
Mineshi, S.8
Ambinder, R.9
Fenske, T.10
-
83
-
-
84890284204
-
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase iii trial of chop-rituximab versus chop + 131iodine—Tositumomab
-
[CrossRef][PubMed]
-
Press, O.W.; Unger, J.M.; Rimsza, L.M.; Friedberg, J.W.; LeBlanc, M.; Czuczman, M.S.; Kaminski, M.; Braziel, R.M.; Spier, C.; Gopal, A.K.; et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase iii trial of chop-rituximab versus chop + 131iodine—Tositumomab. Clin. Cancer Res. 2013, 19, 6624–6632. [CrossRef][PubMed]
-
(2013)
Clin. Cancer Res
, vol.19
, pp. 6624-6632
-
-
Press, O.W.1
Unger, J.M.2
Rimsza, L.M.3
Friedberg, J.W.4
Leblanc, M.5
Czuczman, M.S.6
Kaminski, M.7
Braziel, R.M.8
Spier, C.9
Gopal, A.K.10
-
84
-
-
0041736032
-
Hla class ii antibodies in the treatment of hematologic malignancies
-
CrossRef
-
Dechant, M.; Bruenke, J.; Valerius, T. Hla class ii antibodies in the treatment of hematologic malignancies. Semin. Oncol. 2003, 30, 465–475. [CrossRef]
-
(2003)
Semin. Oncol
, vol.30
, pp. 465-475
-
-
Dechant, M.1
Bruenke, J.2
Valerius, T.3
-
85
-
-
84863637447
-
Targeted radioimmunotherapy: The role of 131I-chtnt-1/b mab (cotara) for treatment of high-grade gliomas
-
[CrossRef][PubMed]
-
Hdeib, A.; Sloan, A. Targeted radioimmunotherapy: The role of 131I-chtnt-1/b mab (cotara) for treatment of high-grade gliomas. Future Oncol. 2012, 8, 659–669. [CrossRef][PubMed]
-
(2012)
Future Oncol
, vol.8
, pp. 659-669
-
-
Hdeib, A.1
Sloan, A.2
-
86
-
-
84876097155
-
Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation
-
[CrossRef][PubMed]
-
Fujiki, M.; Aucejo, F.; Kim, R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: Do we really need this? Clin. Transplant. 2013, 27, 169–177. [CrossRef][PubMed]
-
(2013)
Do We Really Need This? Clin. Transplant.
, vol.27
, pp. 169-177
-
-
Fujiki, M.1
Aucejo, F.2
Kim, R.3
-
87
-
-
84861894823
-
-
[CrossRef][PubMed]
-
Erba, P.A.; Sollini, M.; Orciuolo, E.; Traino, C.; Petrini, M.; Paganelli, G.; Bombardieri, E.; Grana, C.; Giovannoni, L.; Neri, D.; et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J. Nucl. Med. 2012, 53, 922–927. [CrossRef][PubMed]
-
(2012)
J. Nucl. Med
, vol.53
, pp. 922-927
-
-
Erba, P.A.1
Sollini, M.2
Orciuolo, E.3
Traino, C.4
Petrini, M.5
Paganelli, G.6
Bombardieri, E.7
Grana, C.8
Giovannoni, L.9
-
89
-
-
84925321749
-
Radium-223 in the treatment of osteoblastic metastases: A critical clinical review
-
[CrossRef][PubMed]
-
Humm, J.L.; Sartor, O.; Parker, C.; Bruland, O.S.; Macklis, R. Radium-223 in the treatment of osteoblastic metastases: A critical clinical review. Int. J. Radiat. Oncol. Biol. Phys. 2015, 91, 898–906. [CrossRef][PubMed]
-
(2015)
Int. J. Radiat. Oncol. Biol. Phys
, vol.91
, pp. 898-906
-
-
Humm, J.L.1
Sartor, O.2
Parker, C.3
Bruland, O.S.4
Macklis, R.5
-
90
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
[CrossRef][PubMed]
-
Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O'Sullivan, J.M.; Fossa, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013, 369, 213–223. [CrossRef][PubMed]
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
Helle, S.I.4
O'sullivan, J.M.5
Fossa, S.D.6
Chodacki, A.7
Wiechno, P.8
Logue, J.9
Seke, M.10
-
91
-
-
84962149233
-
177-Lu-dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the Phase III NETTER-1 trial
-
Vienna, Austria, 25–29 September
-
Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Mittra, E.; Hobday, T.; Hendifar, A., et al. 177-Lu-dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the Phase III NETTER-1 trial. In Proceedings of the 2015 European Cancer Congress, Vienna, Austria, 25–29 September 2015; p. 6LBA.
-
(2015)
Proceedings of the 2015 European Cancer Congress
-
-
Strosberg, J.1
Wolin, E.2
Chasen, B.3
Kulke, M.4
Bushnell, D.5
Caplin, M.6
Baum, R.P.7
Mittra, E.8
Hobday, T.9
Hendifar, A.10
-
92
-
-
84927153593
-
Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma
-
[CrossRef][PubMed]
-
Kayano, D.; Kinuya, S. Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: Reports so far and future perspective. Sci. World J. 2015, 2015, 1–9. [CrossRef][PubMed]
-
(2015)
Reports So Far and Future Perspective. Sci. World J.
, vol.2015
, pp. 1-9
-
-
Kayano, D.1
Kinuya, S.2
-
93
-
-
78650143642
-
Thyroid and hepatic function after high dose (131)i-metaiodobenzylguanidine ((131)i-mibg) therapy for neuroblastoma
-
[CrossRef][PubMed]
-
Quach, A.; Ji, L.; Mishra, V.; Sznewajs, A.; Veatch, J.; Huberty, J.; Franc, B.; Sposto, R.; Groshen, S.; Wei, D., et al. Thyroid and hepatic function after high dose (131)i-metaiodobenzylguanidine ((131)i-mibg) therapy for neuroblastoma. Pediatr. Blood Cancer 2011, 56, 191–201. [CrossRef][PubMed]
-
(2011)
Pediatr. Blood Cancer
, vol.56
, pp. 191-201
-
-
Quach, A.1
Ji, L.2
Mishra, V.3
Sznewajs, A.4
Veatch, J.5
Huberty, J.6
Franc, B.7
Sposto, R.8
Groshen, S.9
Wei, D.10
-
94
-
-
84941979029
-
Phase I study of vorinostat as a radiation sensitizer with 131i-metaiodobenzylguanidine (131i-mibg) for patients with relapsed or refractory neuroblastoma
-
[CrossRef][PubMed]
-
DuBois, S.G.; Groshen, S.; Park, J.R.; Haas-Kogan, D.A.; Yang, X.; Geier, E.; Chen, E.; Giacomini, K.; Weiss, B.; Cohn, S.L., et al. Phase I study of vorinostat as a radiation sensitizer with 131i-metaiodobenzylguanidine (131i-mibg) for patients with relapsed or refractory neuroblastoma. Clin. Cancer Res. 2015, 21, 2715–2721. [CrossRef][PubMed]
-
(2015)
Clin. Cancer Res
, vol.21
, pp. 2715-2721
-
-
Dubois, S.G.1
Groshen, S.2
Park, J.R.3
Haas-Kogan, D.A.4
Yang, X.5
Geier, E.6
Chen, E.7
Giacomini, K.8
Weiss, B.9
Cohn, S.L.10
-
95
-
-
84943661827
-
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)i-metaiodobenzylguanidine ((131)i-mibg)
-
[CrossRef][PubMed]
-
Zhou, M.J.; Doral, M.Y.; DuBois, S.G.; Villablanca, J.G.; Yanik, G.A.; Matthay, K.K. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)i-metaiodobenzylguanidine ((131)i-mibg). Eur. J. Cancer 2015, 51, 2465–2472. [CrossRef][PubMed]
-
(2015)
Eur. J. Cancer
, vol.51
, pp. 2465-2472
-
-
Zhou, M.J.1
Doral, M.Y.2
Dubois, S.G.3
Villablanca, J.G.4
Yanik, G.A.5
Matthay, K.K.6
-
96
-
-
84944447692
-
Radioprotective substances: History, trends and prospects
-
CrossRef
-
Gudkov, S.V.; Popova, N.R.; Bruskov V.I. Radioprotective substances: History, trends and prospects. Biophysics 2015, 60, 659–667. [CrossRef]
-
(2015)
Biophysics
, vol.60
, pp. 659-667
-
-
Gudkov, S.V.1
Popova, N.R.2
Bruskov, V.I.3
-
97
-
-
33646442741
-
Guanosine and inosine display antioxidant activity, protect DNA in vitro from oxidative damage induced by reactive oxygen species, and serve as radioprotectors in mice. Radiat
-
[CrossRef][PubMed]
-
Gudkov, S.V.; Shtarkman, I.N.; Smirnova, V.S.; Chernikov, A.V.; Bruskov V.I. Guanosine and inosine display antioxidant activity, protect DNA in vitro from oxidative damage induced by reactive oxygen species, and serve as radioprotectors in mice. Radiat. Res. 2006, 165, 538–545. [CrossRef][PubMed]
-
(2006)
Res
, vol.165
, pp. 538-545
-
-
Gudkov, S.V.1
Shtarkman, I.N.2
Smirnova, V.S.3
Chernikov, A.V.4
Bruskov, V.I.5
-
98
-
-
65649124554
-
Protection of mice against X-ray injuries by the post-irradiation administration of guanosine and inosine
-
[CrossRef][PubMed]
-
Gudkov, S.V.; Gudkova, O.Y.; Chernikov, A.V.; Bruskov V.I. Protection of mice against X-ray injuries by the post-irradiation administration of guanosine and inosine. Int. J. Radiat. Biol. 2009, 85, 116–125. [CrossRef][PubMed]
-
(2009)
. Int. J. Radiat. Biol.
, vol.85
, pp. 116-125
-
-
Gudkov, S.V.1
Gudkova, O.Y.2
Chernikov, A.V.3
Bruskov, V.I.4
-
99
-
-
77957973755
-
Antioxidative and radiation modulating properties of guanosine-51-monophosphate
-
[CrossRef][PubMed]
-
Asadullina, N.R.; Usacheva, A.M.; Smirnova, V.S.; Gudkov, S.V. Antioxidative and radiation modulating properties of guanosine-51-monophosphate. Nucleosides Nucleotides Nucleic Acid 2010, 29, 786–799. [CrossRef][PubMed]
-
(2010)
Nucleosides Nucleotides Nucleic Acid
, vol.29
, pp. 786-799
-
-
Asadullina, N.R.1
Usacheva, A.M.2
Smirnova, V.S.3
Gudkov, S.V.4
|